Lab Phone 212-639-2354 Email KovatchM@sloankettering.edu Dissertation New roles for old proteins: MDM2 and ATRX drive the transition from quiescence to senescence (2017) Mentor Andrew Koff, PhD Start Year 2010 End Year 2017 Education University of Toronto Fellowships Grayer Fellowship (2012-2013) Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarship (2011-2012) Publications Kovatcheva M, Klein ME, Tap WD, Koff A. (2017) Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors. Mol Cell Oncol. 5, e1384882. PMCID: PMC5791849. [Available on 2018-11-07] Klein ME, Kovatcheva M, Davis LE, Tap WD, Koff A. (2018) CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought. Cancer Cell. [Epub ahead of print] Kovatcheva M, Liao W, Klein ME, Robine N, Geiger H, Crago AM, Dickson MA, Tap WD, Singer S, Koff A. (2017) ATRX is a regulator of therapy induced senescence in human cells. Nat Commun. 8, 386. PMCID: PMC5577318 Kovatcheva M, Liu DD, Dickson MA, Klein ME, O’Connor R, Wilder FO, Socci ND, Tap WD, Schwartz GK, Singer S, Crago AM, Koff A. (2015) MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget, 6, 8226-43. PMCID: PMC4480747. My Events New roles for old proteins: MDM2 and ATRX drive the transition from quiescence to senescence
